ArticleBMC infectious diseases2025
The role of serum lactate and hypotension in mortality risk stratification for critically ill COVID-19 patients: insights from a large retrospective ICU cohort.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolomics in Infectious Diseases and Vaccine Response: Insights into Neglected Tropical and Non-Neglected Pathogens.Infectious disease reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the association of serum lactate levels with ICU outcomes in COVID-19 patients, particularly concerning hypotension, shock, and mortality.
methodsRetrospective single center cohort study conducted in the intensive care unit. Adult patients (≥ 18 years) pneumonia admitted to the ICU with confirmed COVID-19 between March 2020 and December 2021. Patients were categorized into four lactate level categories: Very Low (< 1.7 mmol/L), Low (1.7-2.1 mmol/L), Intermediate (2.1-2.7 mmol/L), and High (> 2.7 mmol/L). Univariate and multivariate stepwise logistic regression analyses were conducted to identify independent predictors of all-cause mortality. The primary outcome was in-hospital mortality.
resultsAmong the 1,371 patients studied, in-hospital mortality rates increased progressively across lactate categories, with 23% in the Very Low category, 31% in the Low category, 38% in the Intermediate category, and 51% in the High category (p < 0.001). Relative risk of in-hospital mortality was 1.37 (95% CI 0.99-1.89; p = 0.14) for the Low category, 1.66 (95% CI 1.23-2.23; p = 0.018) for the Intermediate category, and 2.24 (95% CI 1.69-2.97; p < 0.001) for the High category, compared to Very Low category. After regrouping the "Very Low" and "Low" categories as "Lower" (n = 446) and the "Intermediate" and "High" categories as "Higher" (n = 925), the mortality rate was 22.8% in the "Lower" category and 77.2% in the "Higher" category (RR 1.63 CI 95% 1.38-1.92) (Pearson Chi-Square, p < 0.001). The presence of hypotension significantly increased the risk of death across all categories, with relative risks ranging from 4.38 to 5.81.
conclusionElevated lactate levels are associated with increased mortality, and hypotension significantly exacerbates this risk across all lactate categories, highlighting its strong predictive power for adverse outcomes in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.